Rituximab for the first-line treatment of stage III-IV follicular lymphoma

TA243 Follicular lymphoma - rituximab (review): review decision - August 2014 information

TA243 Follicular lymphoma - rituximab (review): appendix a - decision paper presented to the Institute's Guidance Executive

TA243 Follicular lymphoma - rituximab (review): appendix a - decision paper presented to the Institute's Guidance Executive (PDF 107 KB)

TA243 Follicular lymphoma - rituximab (review): review proposal - June 2014 information

Appendix A: matrix of stakeholders

Appendix A: matrix of stakeholders (PDF 99 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Follicular lymphoma - rituximab (review): EIA

Follicular lymphoma - rituximab (review): final appraisal determination information

Follicular lymphoma - rituximab (review): final appraisal determination

Follicular lymphoma - rituximab (review): final appraisal determination (PDF 232 KB)

Follicular lymphoma - rituximab (review): response to consultee, commentator and public comments on the appraisal consultation document (ACD)

Follicular lymphoma - rituximab (review): response to consultee, commentator and public comments on the appraisal consultation document (ACD) (PDF 162 KB)

Follicular lymphoma - rituximab (review): consultee and commentator comments on the ACD

Follicular lymphoma - rituximab (review): comments from School of Health and Related Research

Follicular lymphoma - rituximab (review): comments from School of Health and Related Research (PDF 52 KB)

Follicular lymphoma - rituximab (review): comments from Roche Pharmaceuticals

Follicular lymphoma - rituximab (review): comments from Roche Pharmaceuticals (PDF 175 KB)

Follicular lymphoma - rituximab (review): comments from Lymphoma association and Leukaemia Care

Follicular lymphoma - rituximab (review): comments from Lymphoma association and Leukaemia Care (PDF 61 KB)

Follicular lymphoma - rituximab (review): comments from Royal College of Physicians

Follicular lymphoma - rituximab (review): comments from Royal College of Physicians (PDF 204 KB)

Follicular lymphoma - rituximab (review): comments from Healthcare Improvement Scotland

Follicular lymphoma - rituximab (review): comments from Healthcare Improvement Scotland (PDF 62 KB)

Follicular lymphoma - rituximab (review): comments from Commissioning Support Appraisals Service

Follicular lymphoma - rituximab (review): comments from Commissioning Support Appraisals Service (PDF 376 KB)

Follicular lymphoma - rituximab (review): expert comments - Parker (clinical expert)

Follicular lymphoma - rituximab (review): expert comments - Parker (clinical expert) (PDF 47 KB)

Follicular lymphoma - rituximab (review): comments on the ACD received from the public through the NICE website

Follicular lymphoma - rituximab (review): appraisal consultation

Follicular lymphoma - rituximab (review): appraisal consultation document information

Follicular lymphoma - rituximab (review): evaluation report

Follicular lymphoma - rituximab (review): overview

Follicular lymphoma - rituximab (review): overview (PDF 236 KB)

Follicular lymphoma - rituximab (review): assessment report

Follicular lymphoma - rituximab (review): assessment report

Follicular lymphoma - rituximab (review): assessment report (PDF 2.64 MB)

Follicular lymphoma - rituximab (review): erratum to assessment report

Follicular lymphoma - rituximab (review): erratum to assessment report (PDF 29 KB)

Follicular lymphoma - rituximab (review): consultee and commentator comments on the assessment report

Follicular lymphoma - rituximab (review): Roche

Follicular lymphoma - rituximab (review): Roche (PDF 92 KB)

Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland

Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland comments 1

Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland comments 1 (PDF 34 KB)

Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland comments 2

Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland comments 2 (PDF 150 KB)

Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the assessment report

Follicular lymphoma - rituximab (review): Assessment Group response to comments from Roche

Follicular lymphoma - rituximab (review): Assessment Group response to comments from Roche (PDF 16 KB)

Follicular lymphoma - rituximab (review): Assessment Group response to Healthcare Improvement Scotland

Follicular lymphoma - rituximab (review): Assessment Group response to Healthcare Improvement Scotland (PDF 37 KB)

Follicular lymphoma - rituximab (review): Roche executive summary

Follicular lymphoma - rituximab (review): Roche executive summary (PDF 96 KB)

Follicular lymphoma - rituximab (review): non-manufacturer submission

Follicular lymphoma - rituximab (review): Lymphoma Association

Follicular lymphoma - rituximab (review): Lymphoma Association (PDF 37 KB)

Follicular lymphoma - rituximab (review): Royal College of Pathologists and British Society for Haematology

Follicular lymphoma - rituximab (review): Royal College of Pathologists and British Society for Haematology (PDF 32 KB)

Follicular lymphoma - rituximab (review): NHS North of Tyne

Follicular lymphoma - rituximab (review): NHS North of Tyne (PDF 30 KB)

Follicular lymphoma - rituximab (review): expert written personal statements

Follicular lymphoma - rituximab (review): Barton

Follicular lymphoma - rituximab (review): Barton (PDF 1.13 MB)

Follicular lymphoma - rituximab (review): Jolliffe

Follicular lymphoma - rituximab (review): Jolliffe (PDF 19 KB)

Follicular lymphoma - rituximab (review): Parker

Follicular lymphoma - rituximab (review): assessment report consultation 

Follicular lymphoma - rituximab (review): protocol

Follicular lymphoma - rituximab (review): final scope

Follicular lymphoma - rituximab (review): final matrix

Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the draft scope

Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the provisional matrix of consultees and commentators

Follicular lymphoma - rituximab (review): appendix A - draft scope

Follicular lymphoma - rituximab (review): appendix B - provisional matrix of consultees and commentators